Immunotherapy

Communities of bacteria known as biofilms are notorious for forming on implanted medical devices and tissues in the body, where they give rise to chronic, sometimes life-threatening infections

Study points to strategies for improving outcomes with immunotherapy in rare cancer type

A new study addresses a central conundrum of CAR-T therapies: their tendency to provoke potentially deadly runaway immune responses against healthy tissues in patients

Study identifies tertiary lymphoid structures as a potential target for improving response to melanoma immunotherapy

Immune checkpoint inhibitors are transforming the field of cancer therapeutics, but their successes are limited by the lack of biomarkers that identify patients most likely to respond

Randomized trial shows benefit of belantamab mafodotin in relapsed/refractory patients

Recent study finds that one in 20 men with end-stage prostate cancer responded to the immunotherapy pembrolizumab 

Recent discovery helps scientists understand why some tumors lack immune cell infiltration and are therefore unresponsive to newer PD-1 targeted therapies 

Killer T cells identified in blood that can hone in on mutations uniquely expressed in cancer cells pave the way for an alternative and personalized therapeutic avenue

Findings might help predict who will react poorly to certain therapies